A phase I, randomized study of combined IL-2 and therapeutic immunisation with antiretroviral therapy

Table 2 Patient HLA types and ELISpot results, showing the sum of delta (background subtracted) IFN-γ spot forming cells (SFC) at weeks 0, 16 and 65 for each patient for whom ELISpot analysis was possible.

Patient	HLA type (peptides used)	Sum of Δ IFN-γ SFC/10⁶ PBMC
		Week 0			Week 16			Week 65
Group A		Gag	Pol	Nef	Gag	Pol	Nef	Gag	Pol	Nef
1	A1 (g1) A2 (g2, p1, p2, p3, n1) B7 (g8, n2) B18 (n8)	20	20	260	0	0	150	20	10	680
16	A2, (g2, p1, p2, p3, n1) B44 (g17, p13, p14)	50	90	110	940	850	320	740	1200	20
36	A2, (g2, p1, p2, p3) A23, (g13) B27, (n9) B49 (n8)	F	F	F	70	60	30	230	280	370
52	A11, (g4, g5, p5, n2) A9, (none identified) B35^A, (g14, p10) B61 (g23, p15, n13)	670	470	295	910	405	1280	370	215	165
54	A2, (g2, p2, n1) A11, (g5, p5) B27, (n9) B35^A (g14, p10)	80	190	30	F	F	F	290	240	160
Group B		Gag	Pol	Nef	Gag	Pol	Nef	Gag	Pol	Nef
7	A2, (g2, p2, p3, n1) A24, (g6) B55, (g18) B57^B (g19, g20, 21, g22)	500	30	0	1310	120	20	1340	190	0
35	A3, (g3) A32, (p8) B7 (g8, n5)	50	110	75	130	70	25	185	135	115
57	A1, (g1) B8 (g9, g10, g11, g12, p9, n6, n7)	490	50	130	190	30	20	450	70	120
Group C		Gag	Pol	Nef	Gag	Pol	Nef	Gag	Pol	Nef
4	A1, (g1) A26, (g7) B27, (n9) B57^B(g19, g20, g21, g22, n12)	220	nd	50	130	nd	40	520	nd	60
11	A1, (g1) A2, (g2, p1, p2, p3, n1) B35^A, (g14, g15, g16, p10, p11, p12, n10, n11) B57^B(g19, g20, g21, g22, n12)	3820	3140	2990	90	50	20	2820	2760	960
14	A1, (g1) A2, (g2, p1, p2, p3, n1) B57^B,(g19, g20, g21, g22, n12) B62 (none identified)	F	F	F	1140	130	20	100	30	70
34	A3, (g3) A29, (p7) B35^A, (g14, g15, p10, n10) B44 (g17, p13, p14)	320	100	0	F	F	F	520	80	10
Group D		Gag	Pol	Nef	Gag	Pol	Nef	Gag	Pol	Nef
13	A2, (g2, p1, p2, n1) A11, (g4, p4, n2) B8, (g9, p9, n6) B62 (none identified)	50	20	70	730	1890	1190	390	640	240
22	A1, (g1) A2, (g2, p2, n1) B7, (g8, n5) B35^A (g14, g15, p10, n11)	270	80	120	F	F	F	60	40	260

F denotes assay failure. IFN-γ (interferon-gamma), PBMC (peripheral blood mononuclear cells), SFC (spot forming cells). ^AHLA B35 is associated with rapid progression in HIV-1 infection. ^BHLA B57 is associated with slow/non progression in HIV-1 infection.